ORGO Fires Clinical Win After Two-Year Reimbursement Beatdown

What Sextant Sees

GSS: 62 | Resonance: 0 | Tension: relaxing
Active Patterns: None
Theoretical: FOMO Ignition, Wrong Consensus Meets Deadline
Dimensions: M:9.8 C:5.2 D:3 S:6 CP:1 Mg-Q:8 Mg-T:7
Velocity: fading: C_rsi_oversold -4, S_below_book -3 (8 scans)

Organogenesis makes skin substitutes and placental grafts for wound care.

THE CHOKEPOINT

ORGO controls PuraPly AM, the only antimicrobial skin substitute combining native collagen with polyhexamethylene biguanide (PHMB) to manage bioburden in diabetic foot ulcers. Short interest stands at 8.39% of float while the company holds FDA approvals across multiple wound care categories. Most competitors cannot replicate the dual-action antimicrobial matrix or the clinical data backing it.

WHY IT FLAGGED TODAY

The scanner caught maximum short interest and analyst coverage converging with 52-week lows. PuraPly AM just posted statistically significant wound closure at 12 weeks in a 170-patient randomized controlled trial. ORGO faces 25-38% revenue decline in 2026 from CMS reimbursement changes but RCT-backed evidence de-risks coverage decisions. The market is discounting severe but temporary revenue pressure at 0.7x EV/sales.

WATCH FOR

Q1 2026 earnings on May 7th after market close with management call at 5:00 PM Eastern. FDA meeting completed for ReNu BLA submission planned before December 2026.

THE ASYMMETRY

Upside: Clear re-rating opportunity if reimbursement stabilizes with valuation at distressed levels. Downside: Revenue cliff continues deeper into 2027 if clinical data fails to restore payer confidence.

Full entry window, exit conditions, and score trajectory available to Pro members at damonskyeresearch.com